Fig. 11. PET scans of C57Bl/6j mice administered 5–6 MBq of 89Zr-YM103-trastuzumab (top) and 89Zr-DFO-trastuzumab (bottom). PET images corroborate ex vivo biodistribution data, with the skeleton of the animal administered 89Zr-YM103-trastuzumab clearly visible from 3 days PI. This is in marked contrast to the animal administered 89Zr-DFO-trastuzumab, where the blood pool remains visible out to 7 days PI.
